RU2001120701A - Новые лиганды тиреоидных рецепторов - Google Patents
Новые лиганды тиреоидных рецепторов Download PDFInfo
- Publication number
- RU2001120701A RU2001120701A RU2001120701/04A RU2001120701A RU2001120701A RU 2001120701 A RU2001120701 A RU 2001120701A RU 2001120701/04 A RU2001120701/04 A RU 2001120701/04A RU 2001120701 A RU2001120701 A RU 2001120701A RU 2001120701 A RU2001120701 A RU 2001120701A
- Authority
- RU
- Russia
- Prior art keywords
- hydroxy
- isopropylphenoxy
- dibromo
- benzoyl
- compound according
- Prior art date
Links
- CJYIEMJRALMYLB-UHFFFAOYSA-N CC(C)NCCc1cnc[nH]1 Chemical compound CC(C)NCCc1cnc[nH]1 CJYIEMJRALMYLB-UHFFFAOYSA-N 0.000 description 1
- NXONIPCBEYLWBD-UHFFFAOYSA-N CNCCNc(nc1)ccc1[N+]([O-])=O Chemical compound CNCCNc(nc1)ccc1[N+]([O-])=O NXONIPCBEYLWBD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Claims (29)
1. Соединения, имеющие формулу
где n=0-4;
R1 обозначает галоген, трифторметил или алкил с 1-6 атомами углерода, или циклоалкил с 3-7 атомами углерода;
R2 и R3, одинаковые или различные, обозначают водород, галоген, алкил с 1-4 атомами углерода, причем, по меньшей мере один из R2 и R3 в соединении не является водородом;
R4 обозначает гетероароматический фрагмент, который может быть замещенным или незамещенным и связан с (СН2)n через атом азота или атом углерода; аминогруппа (NR’R’’), включая группы, альфа-аминокислоты природной (L) или синтетической (D) стереохимии; ацилсульфонамидную группу (CONHSO2R’); или амидогруппу карбоновой кислоты (CONR’R’’) при условии, что когда n=0 (n=0), R4 может быть только амидной группой карбоновой кислоты или ацилсульфонамидной группой;
R5 обозначает водород или ацил (такой как ацетил или бензил) или другую группу, способную к биоконверсии с получением свободной фенольной структуры (где R5=Н);
включая все его стереоизомеры, эфирные пролекарства и фармацевтически приемлемые соли.
2. Соединение по п.1, отличающееся тем, что R4 обозначает амидную группу карбоновой кислоты (CONR’R’’), в которой аминная часть может быть группой ахиральной или L или D альфа-аминокислоты, такой когда общая структура -CONR’R’’ может обозначать:
R’, R’’, R’’’ и R’’’’, одинаковые или разные, независимо выбираются из водорода, алкила, арила и гетероарила, замещенного или незамещенного, и R* может быть водородом, алкилом, арилом и гетероарилом, замещенным или незамещенным, и может также быть любой из боковых цепей, находящихся в природных альфа-аминокислотах.
3. Соединение по п.2, отличающееся тем, что R’ и R* соединены друг с другом с образованием 4-8-членного кольца.
4. Соединение по п.2, отличающееся тем, что R’ и R* входят в состав последовательных -(СН2)- групп с образованием пролина или гомопролина.
5. Соединение по п.1, отличающееся тем, что n=0 или 1, или 2.
6. Соединение по п.1, отличающееся тем, что R2 и R3, каждый независимо, обозначает галоген.
7. Соединение по п.1, отличающееся тем, что R2 и R3, каждый независимо, обозначает алкил.
8. Соединение по п.1, отличающееся тем, что один из R2 и R3 обозначает галоген, а другой - алкил.
9. Соединение по п.1, отличающееся тем, что один из R2 и R3 обозначает галоген, а другой - водород.
10. Соединение по п.1, отличающееся тем, что один из R2 и R3 обозначает алкил, а другой - водород.
11. Соединение по п.1, отличающееся тем, что R2 и R3, независимо, обозначают Cl, Br, метил или этил.
12. Соединение по п.1, отличающееся тем, что R1 обозначает изопропил.
13. Соединение по п.1, отличающееся тем, что R4 обозначает гетероароматический углеводородный радикал, амидную группу карбоновой кислоты или ацилсульфонамидную группу.
14. Соединение по п.1, отличающееся тем, что R5 обозначает водород.
15. Соединение по п.1, отличающееся тем, что оно представляет собой:
3,5-диметил-4-(4-гидрокси-3-изопропилфенокси)бензилтетразол;
3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси) бензилтетразол;
2-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензил]-4-тиазолуксусную кислоту;
2-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензил]-4-метилтиазол.
16. Соединение по п.1, отличающееся тем, что оно представляет собой:
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-5-гидрокси-1-нафталинсульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-толуолсульфон-амид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-нитробензол-сульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоилсульфамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-5-диметиламино-1-нафталинсульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-аминобензол-сульфонамид;
метил-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-2-сульфон-амид]бензоат;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-2-аминобензол-сульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-2-толуолсульфон-амид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-(2-аминоэтил)-бензолсульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-(2-аминометил)-бензолсульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-3-нитробензол-сульфонамид;
3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил-4-хлорбензол-сульфонамид;
и соединения, представленные ниже
18. Соединение по п.1, отличающееся тем, что оно представляет собой:
D,N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]валин,
D,N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]лейцин,
L-S-бензил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]-цистеин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]тирозин,
L-N-d-(2,2,5,7,8-пентаметилхроман-6-сульфонил),
N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]аргинин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]амино-масляная кислота,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]валин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]лейцин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]пролин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]цистеин,
N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]глицин,
L-N-а-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]лизин,
D-N-а-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]лизин,
N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]аминоизо-масляная кислота,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]фенилглицин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]фенилглицин,
N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]саркозин,
D,L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]-а-метил-фенилаланин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]изолейцин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]метионин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]метионин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]фенилаланин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]фенилаланин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]циклогексил-аланин,
L-N-е-(бензилоксикарбонил)N-а-[3,5-дибром-4-(4-гидрокси-3-изопропил-фенокси)бензоил]лизин,
D-N-е-(бензилоксикарбонил)N-а-[3,5-дибром-4-(4-гидрокси-3-изопропил-фенокси)бензоил]лизин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил] гомосерин,
N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]глицин,
N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]саркозин,
3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)фенилформилиминоди-уксусная кислота,
N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)бензоил]-бета-аланин,
N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]бета-аланин,
D-N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]метионин,
L-N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]серин,
D-N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]серин,
L-N-[3,5-дихлор-4-(4-гидрокси-3-изопропилфенокси)бензоил]серин,
N-[3,5-дихлор-4-(4-гидрокси-3-бромфенокси)бензоил]глицин,
N-[3,5-дихлор-4-(4-гидрокси-3-метилфенокси)бензоил]глицин,
N-[3,5-дихлор-4-(4-гидрокси-3-этилфенокси)бензоил]глицин.
19. Соединение по п.1, отличающееся тем, что оно представляет собой
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-метионин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-метионин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-а-метилаланин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-аспаргин,
L-метил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-аланин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]аланин,
L-диметил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутамат,
L-диметил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутамат,
L-(O-трет.бутил)метил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)-фенилацетил]глутамат,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутаминовую кислоту,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-аспартовую кислоту,
D-ди-трет.бутил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)-фенилацетил]глутамат,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутаминовую кислоту,
L-O-трет.бутил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)-фенилацетил]глутамин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутамин,
D-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-глутамин,
L-O-бензил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенил-ацетил]аспартовую кислоту,
L-O-трет.бутил-Н-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенил-ацетил]аспарагин,
L-метил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-гомосерин,
L-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-гомосерин,
D-метил-N-[3,5-дибром-4-(4-гидрокси-3-изопропилфенокси)фенилацетил]-гомосерин
и соединения, приведенные ниже в таблице:
22. Соединения по п.1, имеющие формулы
где R1 обозначает изопропил, метил, этил;
R2 и R3 могут быть независимо выбраны из Br, Cl и Me;
n=0 или 1;
R* может обозначать водород, алкил, циклоалкил, арил и гетероарил;
* обозначает D- или L-стереохимию, когда R* не является водородом;
R5 обозначает водород;
R’ выбран из водорода, низшего алкила, особенно, этила и метила.
23. Способ профилактики, ингибирования или лечения болезни, связанной с дисфункцией метаболизма или зависящей от экспрессии регулируемого Т3 гена, включающий введение пациенту, нуждающемуся в таком лечении, терапевтически эффективного количества соединения по п.1.
24. Способ по п.23, отличающийся тем, что болезнь, связанная с дисфункцией метаболизма или зависящая от экспрессии регулируемого Т3 гена, представляет собой ожирение, гиперхолестеринемию, атеросклероз, депрессию, остеопороз, гипотиреоз, струму, рак щитовидной железы, глаукому, сердечную аритмию, застойную сердечную недостаточность или кожные заболевания.
25. Применение соединения по п.1 для приготовления лекарства для лечения болезни или заболеваний, зависящих от экспрессии регулируемого Т3 гена.
26. Применение соединения по п.1, заключающееся в том, что болезнь или заболевание выбраны из гипотиреоза, гиперхолестеринемии, ожирения, заболеваний кожи, глаукомы, сердечно-сосудистого заболевания, застойной сердечной недостаточности и других эндокринных заболеваний, связанных с тиреоидным гормоном.
27. Фармацевтическая композиция, содержащая эффективное количество соединения по п.1 или его фармацевтически эффективную соль в сочетании с фармацевтически приемлемым носителем.
28. Способ по п.24, отличающийся тем, что кожное заболевание или болезнь представляет собой дермальную атрофию, послехирургические кровоподтеки, вызванные воздействием лазера, келоиды, атрофическую полоску, целлюлит, огрубевшую кожу, актиническое повреждение кожи, красный плоский лишай, ихтиоз, угри, псориаз, болезнь Дернье, экзему, атонический дерматит, хлоракне, питириаз и шрамы на коже.
29. Способ лечения кожного заболевания или болезни путем использования соединения по п.1 в сочетании с ретиноидом или аналогом витамина D.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828442.5A GB9828442D0 (en) | 1998-12-24 | 1998-12-24 | Novel thyroid receptor ligands and method II |
GB9828442.5 | 1998-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2001120701A true RU2001120701A (ru) | 2003-12-10 |
Family
ID=10844889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001120701/04A RU2001120701A (ru) | 1998-12-24 | 1999-12-23 | Новые лиганды тиреоидных рецепторов |
Country Status (19)
Country | Link |
---|---|
US (2) | US6989402B1 (ru) |
EP (1) | EP1144370A2 (ru) |
JP (1) | JP4405088B2 (ru) |
KR (1) | KR20010108032A (ru) |
CN (1) | CN1186332C (ru) |
AU (1) | AU758202B2 (ru) |
BR (1) | BR9916851A (ru) |
CA (1) | CA2356319A1 (ru) |
CZ (1) | CZ20012204A3 (ru) |
GB (1) | GB9828442D0 (ru) |
HU (1) | HUP0104666A3 (ru) |
ID (1) | ID29013A (ru) |
IL (1) | IL143799A0 (ru) |
NO (1) | NO20012931L (ru) |
NZ (1) | NZ512422A (ru) |
RU (1) | RU2001120701A (ru) |
TR (1) | TR200101834T2 (ru) |
WO (1) | WO2000039077A2 (ru) |
ZA (1) | ZA200104932B (ru) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1127882A1 (en) | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
FI107018B (fi) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
US6395784B1 (en) * | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
US7163918B2 (en) * | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
GB0029100D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
JP2004517851A (ja) | 2000-12-27 | 2004-06-17 | バイエル アクチェンゲゼルシャフト | 甲状腺受容体のリガンドとしてのインドール誘導体 |
US7504435B2 (en) | 2001-01-31 | 2009-03-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for stimulating weight loss and/or for lowering triglycerides in patients |
US7144909B2 (en) | 2001-02-08 | 2006-12-05 | Karo Bio Ab | Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
DE10122443A1 (de) * | 2001-05-09 | 2002-11-14 | Bayer Ag | Amido-Diphenyl-Derivate |
GB0120691D0 (en) * | 2001-08-24 | 2001-10-17 | Karobio Ab | Novel Compounds |
AU2002331145B2 (en) | 2001-08-24 | 2008-07-10 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
ES2253495T3 (es) | 2001-09-26 | 2006-06-01 | Pfizer Products Inc. | Acidos indol carboxilicos como ligandos de receptores tiroideos. |
JPWO2003064369A1 (ja) | 2002-01-30 | 2005-05-26 | キッセイ薬品工業株式会社 | 新規な甲状腺ホルモン受容体リガンド、それを含有する医薬組成物、およびそれらの用途 |
GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
GB0215978D0 (en) * | 2002-07-10 | 2002-08-21 | Karobio Ab | Novel compounds |
CA2499690C (en) * | 2002-09-19 | 2011-05-24 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonist |
EP1477475A1 (en) * | 2003-05-16 | 2004-11-17 | Procorde GmbH | Compounds for use as a medicine increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2005047297A1 (en) * | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
US7795448B2 (en) | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
BRPI0613423A2 (pt) * | 2005-07-19 | 2012-12-11 | Daiichi Sankyo Co Ltd | composição farmacêutica, composto ou um seu sal farmaceuticamente aceitável, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
TW200740435A (en) * | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
MX2008013238A (es) * | 2006-04-12 | 2008-10-21 | Merck & Co Inc | Antagonistas de los canales de calcio de tipo t de piridil amida. |
WO2007120083A1 (en) * | 2006-04-13 | 2007-10-25 | Astrazeneca Ab | The use of carboxamide derivatives in the manufacture of a medicament for the treatment of inflammatory, allergic and dermatological conditions |
WO2007132475A1 (en) * | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
EP2099767A1 (en) | 2006-11-01 | 2009-09-16 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof |
EP2124873B1 (en) | 2007-01-31 | 2016-01-06 | Basf Se | Cationic dyes |
US8399518B2 (en) | 2007-02-27 | 2013-03-19 | University Of Arizona Office Of Technology Transfer | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome |
PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
CN101687873A (zh) | 2007-04-17 | 2010-03-31 | 百时美施贵宝公司 | 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
BRPI0817211A2 (pt) * | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
US8637513B2 (en) * | 2007-10-24 | 2014-01-28 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide T-type calcium channel antagonists |
EP2209780B1 (en) | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
GB0725214D0 (en) * | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
AU2009309229B2 (en) * | 2008-10-27 | 2012-03-15 | Cadila Healthcare Limited | Thyroid receptor ligands |
WO2010058730A1 (ja) | 2008-11-19 | 2010-05-27 | ポーラ化成工業株式会社 | シワ改善剤 |
WO2010086878A2 (en) | 2009-01-09 | 2010-08-05 | Cadila Healthcare Limited | Thyroid receptor modulators |
WO2010111665A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
CN102459185B (zh) * | 2009-04-20 | 2015-06-03 | 田边三菱制药株式会社 | 新型甲状腺激素β受体激动剂 |
HUE040486T2 (hu) | 2009-11-13 | 2019-03-28 | Astrazeneca Ab | Kétrétegû tabletta készítmények |
CA2780941C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Immediate release tablet formulations |
EP2498757A1 (en) | 2009-11-13 | 2012-09-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
WO2011103126A1 (en) * | 2010-02-17 | 2011-08-25 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with piperidine amides |
US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
JP2013532185A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
CA2804877A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
JP2013532186A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
BR112014010368A2 (pt) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
CA2860553C (en) * | 2012-01-04 | 2016-08-23 | Pfizer Limited | N-aminosulfonyl benzamides |
MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
CN102718718B (zh) * | 2012-05-31 | 2014-09-24 | 绍兴文理学院 | 一种3,5-二溴-4-(5-苯并咪唑氧基)苯乙酸的制备方法 |
KR101663436B1 (ko) * | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
US9586900B2 (en) | 2012-09-05 | 2017-03-07 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
EP2892897A1 (en) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
MX2015010775A (es) | 2013-03-15 | 2016-04-25 | Genentech Inc | Benzoxazoles sustituidos y metodos para usarlos. |
US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
CA2931732A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
CN103709094B (zh) * | 2014-01-07 | 2016-04-06 | 厦门大学 | 4-苯氧基苯甲酰胺类化合物及其制备方法和应用 |
CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
BR112017024853A2 (pt) | 2015-05-22 | 2018-08-07 | Genentech Inc | composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto |
EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
JP6987746B2 (ja) | 2015-09-28 | 2022-01-05 | ジェネンテック, インコーポレイテッド | 治療用化合物及びその使用方法 |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
EP3854782A1 (en) | 2016-03-30 | 2021-07-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2017184604A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
WO2018032012A1 (en) * | 2016-08-12 | 2018-02-15 | Oregon Health & Science University | Amide compounds, pharmaceutical compositions thereof, and methods of using the same |
CA3039853A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
CN106588690B (zh) * | 2016-12-19 | 2019-06-04 | 广西中医药大学 | 毛鸡骨草甲素Abrusamide的制备方法 |
EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
JP7360583B2 (ja) | 2017-09-14 | 2023-10-13 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
JP7157804B2 (ja) * | 2017-10-17 | 2022-10-20 | ノバルティス アーゲー | Nlrp活性に関連する病態を治療するためのスルホンアミド及びその組成物 |
WO2019119673A1 (zh) | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | 一种双基因修饰的干细胞及其用途 |
AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
EP3768690A4 (en) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND |
US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
CN113423684A (zh) | 2018-12-12 | 2021-09-21 | 速通医疗公司 | 新型拟甲状腺素药 |
CA3130371A1 (en) | 2019-03-01 | 2020-09-10 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
CN113557311A (zh) | 2019-03-13 | 2021-10-26 | 大日本住友制药株式会社 | 移植用神经视网膜的品质评价方法及移植用神经视网膜片 |
WO2021026179A1 (en) * | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
US20230313133A1 (en) | 2020-09-11 | 2023-10-05 | Riken | Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same |
CN116194079A (zh) | 2020-09-11 | 2023-05-30 | 住友制药株式会社 | 用于移植用组织的介质 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3231541A1 (de) | 1982-08-25 | 1984-03-01 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin | Arzneimittel, enthaltend 3,3',5-trijodthyronamin und verfahren zu seiner herstellung |
US4741897A (en) * | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
ES2108855T3 (es) * | 1992-07-21 | 1998-01-01 | Ciba Geigy Ag | Derivados de acido oxamico como agentes hipocolesteremicos. |
AU6476996A (en) * | 1995-06-07 | 1996-12-30 | Karo Bio Ab | Novel uses for thyroid hormones or thyroid hormone-like comp ounds |
US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
US6395784B1 (en) * | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
-
1998
- 1998-12-24 GB GBGB9828442.5A patent/GB9828442D0/en not_active Ceased
-
1999
- 1999-12-23 CZ CZ20012204A patent/CZ20012204A3/cs unknown
- 1999-12-23 NZ NZ512422A patent/NZ512422A/xx unknown
- 1999-12-23 IL IL14379999A patent/IL143799A0/xx unknown
- 1999-12-23 JP JP2000590990A patent/JP4405088B2/ja not_active Expired - Fee Related
- 1999-12-23 WO PCT/IB1999/002084 patent/WO2000039077A2/en not_active Application Discontinuation
- 1999-12-23 EP EP99962486A patent/EP1144370A2/en not_active Withdrawn
- 1999-12-23 KR KR1020017007766A patent/KR20010108032A/ko not_active Application Discontinuation
- 1999-12-23 BR BR9916851-0A patent/BR9916851A/pt not_active IP Right Cessation
- 1999-12-23 CN CNB998150576A patent/CN1186332C/zh not_active Expired - Fee Related
- 1999-12-23 ID IDW00200101489A patent/ID29013A/id unknown
- 1999-12-23 AU AU18855/00A patent/AU758202B2/en not_active Ceased
- 1999-12-23 CA CA002356319A patent/CA2356319A1/en not_active Abandoned
- 1999-12-23 HU HU0104666A patent/HUP0104666A3/hu unknown
- 1999-12-23 TR TR2001/01834T patent/TR200101834T2/xx unknown
- 1999-12-23 US US09/868,889 patent/US6989402B1/en not_active Expired - Fee Related
- 1999-12-23 RU RU2001120701/04A patent/RU2001120701A/ru not_active Application Discontinuation
-
2001
- 2001-06-13 NO NO20012931A patent/NO20012931L/no not_active Application Discontinuation
- 2001-06-15 ZA ZA200104932A patent/ZA200104932B/en unknown
-
2005
- 2005-07-26 US US11/189,654 patent/US7288571B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU1885500A (en) | 2000-07-31 |
NO20012931L (no) | 2001-08-21 |
CA2356319A1 (en) | 2000-07-06 |
BR9916851A (pt) | 2001-10-16 |
GB9828442D0 (en) | 1999-02-17 |
KR20010108032A (ko) | 2001-12-07 |
ZA200104932B (en) | 2003-01-15 |
US7288571B2 (en) | 2007-10-30 |
JP4405088B2 (ja) | 2010-01-27 |
CN1337953A (zh) | 2002-02-27 |
US6989402B1 (en) | 2006-01-24 |
NZ512422A (en) | 2004-02-27 |
EP1144370A2 (en) | 2001-10-17 |
IL143799A0 (en) | 2002-04-21 |
HUP0104666A2 (hu) | 2002-03-28 |
US20050282872A1 (en) | 2005-12-22 |
TR200101834T2 (tr) | 2001-12-21 |
ID29013A (id) | 2001-07-26 |
WO2000039077A2 (en) | 2000-07-06 |
JP2002533432A (ja) | 2002-10-08 |
HUP0104666A3 (en) | 2003-05-28 |
AU758202B2 (en) | 2003-03-20 |
CZ20012204A3 (cs) | 2001-11-14 |
WO2000039077A3 (en) | 2000-09-21 |
CN1186332C (zh) | 2005-01-26 |
NO20012931D0 (no) | 2001-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001120701A (ru) | Новые лиганды тиреоидных рецепторов | |
JP2004501132A5 (ru) | ||
KR100362424B1 (ko) | 발프로산아미드와2-발프로에노산아미드의유도체및항경련제로서의용도 | |
EP1371640B1 (en) | Novel a-lipoic acid derivative and use thereof | |
ATE494902T1 (de) | Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums | |
RU98109793A (ru) | Триароматические соединения, содержащие их композиции и их применение | |
RU96104545A (ru) | Производные сульфонамидов, способ их получения, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения | |
CA2414008A1 (en) | Gabapentin analogues for sleep disorders | |
KR940018372A (ko) | 피페라진 유도체 | |
JP2948658B2 (ja) | 新規アミノ酸誘導体、その製造方法およびその医薬組成物 | |
RU94035760A (ru) | Опиоидные пептиды | |
JPH02115130A (ja) | 経鼻用カルシトニン製剤 | |
US5359128A (en) | Malic acid derivatives and compositions for the treatment of psoriasis | |
US6552061B1 (en) | Amino acid derivatives and anti-inflammatory agents | |
CA2137897A1 (fr) | Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
JP4313049B2 (ja) | 血管新生関連疾患の予防又は治療用医薬組成物 | |
CA2334941A1 (en) | Tnf-derived peptides for use in treating oedema | |
US5214196A (en) | Diethyl ester of di-glycyl fumaramide | |
CA2304700A1 (en) | Lipophilic diesters of chelating agents | |
EP2647619B1 (en) | Novel compound and medical use thereof | |
JPH06500326A (ja) | N―(メルカプトアルキル)尿素およびカルバミン酸塩 | |
JP2003286168A (ja) | α−リポイルアミノ酸を含有する皮膚外用剤 | |
FR2766366A1 (fr) | Utilisation d'au moins un lipoaminoacide en tant qu'antagoniste de la substance p dans une formulation cosmetique pour apaiser et/ou proteger tous les types de peaux et, notamment, les peaux sensibles | |
CN1121215C (zh) | 氨基酸衍生物和活性氧抗性剂 | |
RU2018136108A (ru) | N-липоевая аминокислота или пептид, производные и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050927 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20051111 |
|
FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20061208 |